BIVI | BioVie Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.4300 - 2.6200
52 Week Range	2.0700 - 58.20
Beta	0.69
Implied Volatility	334.13%
IV Rank	12.24%
Day's Volume	36,387
Average Volume	104,610
Shares Outstanding	6,116,550
Market Cap	15,230,210
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-09-18

Valuation
Profitability
Growth
Health
P/E Ratio	-0.27
Forward P/E Ratio	N/A
EPS	-9.30
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	18
Country	USA
Website	BIVI

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

BIVI's peers: ALT, AVXL, BCRX, INZY, DAWN, TERN, ELDN, HOOK, XFOR, ABOS, MREO, AMLX, GANX, INMB, SAVA, PMN

*Chart delayed

Analyzing fundamentals for BIVI we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see BIVI Fundamentals page.

Watching at BIVI technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on BIVI Technicals page.